Recent Price Movement and Market Context
On 24 Nov 2025, Kopran’s stock price touched Rs.126.6, the lowest level recorded in the past year. This decline comes after two consecutive days of losses, during which the stock has recorded a cumulative return of -5.52%. The day’s performance showed a drop of 1.71%, underperforming its Pharmaceuticals & Biotechnology sector by 1.68%. Kopran’s share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum.
In contrast, the broader market has shown resilience. The Sensex opened 88.12 points higher and was trading at 85,455.79, up 0.26% on the day. The index remains close to its 52-week high of 85,801.70, just 0.4% away, and has recorded a 2.69% gain over the past three weeks. Mega-cap stocks have been leading this rally, with the Sensex trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a bullish trend in the broader market.
Long-Term Performance and Financial Indicators
Kopran’s one-year performance contrasts sharply with the Sensex, showing a negative return of -42.35% compared to the Sensex’s positive 8.01% over the same period. The stock’s 52-week high was Rs.236.1, highlighting the extent of the decline from its peak.
Financially, Kopran has experienced a contraction in net sales by 22.2%, with the company reporting negative results for five consecutive quarters. The latest quarterly profit after tax (PAT) stood at a loss of Rs.9.92 crores, reflecting a fall of 234.4%. Operating profit has shown a negative annual growth rate of 11.79% over the last five years, indicating challenges in sustaining profitability. The company’s return on capital employed (ROCE) for the half-year is at a low 5.38%, while the operating profit to interest ratio for the quarter is at -2.53 times, underscoring financial strain.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Shareholding and Market Interest
Despite Kopran’s size within the Pharmaceuticals & Biotechnology sector, domestic mutual funds hold a minimal stake of just 0.01%. Given that domestic mutual funds typically conduct detailed research on companies, this small holding may reflect a cautious stance towards the stock’s current valuation or business outlook.
Over the past three years, Kopran has underperformed the BSE500 index across multiple time frames, including the last three years, one year, and three months, further emphasising the stock’s subdued market performance.
Valuation and Debt Profile
Kopran maintains a relatively low average debt-to-equity ratio of 0.23 times, which suggests limited leverage compared to many peers. The company’s ROCE stands at 4.7, and it has an enterprise value to capital employed ratio of 1.2, indicating an attractive valuation relative to its capital base. The stock is trading at a discount compared to the average historical valuations of its sector peers.
However, the company’s profits have declined by 66.7% over the past year, aligning with the negative returns generated by the stock during the same period.
Kopran or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Key Financial Challenges
The company’s recent financial disclosures highlight a series of negative results, with the September 2025 quarter marking the fifth consecutive quarter of losses. The operating profit to interest coverage ratio being negative indicates that operating earnings are insufficient to cover interest expenses, a factor that may weigh on financial stability. The low ROCE further points to limited efficiency in generating returns from capital employed.
These financial metrics, combined with the stock’s trading below all major moving averages and its sustained underperformance relative to the sector and broader market, provide a comprehensive picture of the challenges Kopran currently faces.
Market Environment and Sector Performance
While Kopran’s stock has been under pressure, the Pharmaceuticals & Biotechnology sector as a whole has not mirrored this trend to the same extent. The sector’s performance today outpaced Kopran’s by 1.68%, and the broader market indices continue to show strength, supported by mega-cap stocks and positive technical indicators.
This divergence highlights the specific difficulties Kopran is encountering within its operational and financial framework, rather than a sector-wide downturn.
Conclusion
Kopran’s fall to a 52-week low of Rs.126.6 reflects a continuation of a downward trend marked by weak financial results, subdued profitability, and limited market interest from institutional investors. The stock’s performance contrasts with the broader market’s positive momentum and the Pharmaceuticals & Biotechnology sector’s relative stability. The company’s valuation metrics suggest a discounted price relative to peers, but ongoing financial pressures remain evident in recent quarterly results and long-term growth indicators.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
